Innoviva - 21 Year Stock Split History | INVA

Stock split history for Innoviva since 2004. Prices shown are actual historical values and are not adjusted for either splits or dividends. Please see the "Historical Prices" tab for adjusted price values.
Innoviva Annual Stock Splits
Innoviva Quarterly Stock Splits
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.253B $0.359B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $734.922B 56.36
Johnson & Johnson (JNJ) United States $366.710B 15.17
AbbVie (ABBV) United States $322.033B 17.75
Novo Nordisk (NVO) Denmark $305.897B 20.27
Roche Holding AG (RHHBY) Switzerland $260.921B 0.00
Novartis AG (NVS) Switzerland $253.512B 14.48
Merck (MRK) United States $198.623B 10.15
Pfizer (PFE) United States $137.529B 7.54
Sanofi (SNY) France $117.350B 11.56
Bayer (BAYRY) Germany $30.927B 6.30